{"product_id":"can-a-daily-low-dose-aspirin-help-prevent-cancer-insights-from-a-10-year-hong-kong-study","title":"Can a Daily Low-Dose Aspirin Help Prevent Cancer? Insights from a 10-Year Hong Kong Study","description":"\u003cp\u003eAspirin, a common over-the-counter pain reliever, is already well known for protecting the heart and preventing strokes. Now, a massive 10-year study of more than 600,000 people in Hong Kong has strengthened the case that long-term, low-dose aspirin (80 mg daily) may also be a powerful cancer-prevention tool. Researchers found that patients who took aspirin for at least 6 months had a 25% lower overall risk of developing cancer compared to similar patients who never took aspirin. Significant risk reductions were seen for many cancer types, including liver, stomach, colorectal, lung, pancreatic, esophageal, and leukaemia. However, the study also found a concerning 14% increased risk of breast cancer among female aspirin users, urging caution before recommending aspirin for everyone. This comprehensive translation of the research breaks down exactly how the study was conducted, what the numbers mean, and what they could mean for you.\u003c\/p\u003e\n\n\u003ch1\u003eCan a Daily Low-Dose Aspirin Help Prevent Cancer? Insights from a 10-Year Hong Kong Study\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Why Aspirin and Cancer?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#study-methods\"\u003eStudy Methods: How the Research Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#key-findings\"\u003eKey Findings: Detailed Results with All Data\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#subgroup-analysis\"\u003eSubgroup Analysis: Timing, Gender, and Age\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#clinical-implications\"\u003eClinical Implications: What This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations: What This Study Couldn't Prove\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations: Actionable Advice for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eIn a 10-year study of over 600,000 people in Hong Kong, low-dose aspirin (median 80 mg daily) for at least 6 months was linked to a 25% lower overall cancer risk.\u003c\/li\u003e\n\u003cli\u003eRisk reductions were 29–58% for stomach, liver, pancreatic, oesophageal, and colorectal cancers, and 33–35% for leukaemia and lung cancer.\u003c\/li\u003e\n\u003cli\u003eWomen taking aspirin had a 14% higher risk of breast cancer (RR 1.14; 95% CI 1.04–1.25; p=0.004), though absolute numbers were identical (1.6% in both groups).\u003c\/li\u003e\n\u003cli\u003eThis was an observational study, so it cannot prove cause and effect; randomized trials are still needed before promoting aspirin for cancer prevention.\u003c\/li\u003e\n\u003cli\u003eDo not start aspirin for cancer prevention without consulting your doctor, as it carries risks like gastrointestinal bleeding and hemorrhagic stroke, which this study did not measure.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: Why Aspirin and Cancer?\u003c\/h2\u003e\n\n\u003cp\u003eAspirin has been a trusted medication for decades, primarily used to prevent cardiovascular disease (heart attacks and strokes). But over the years, researchers have noticed something remarkable: patients who take aspirin regularly seem to develop certain cancers less often. The question is whether this protection is real and whether it applies to everyone — especially Asian populations, where large studies have been lacking.\u003c\/p\u003e\n\n\u003cp\u003ePrevious research has mostly focused on Western populations with inconsistent results. For example, the US Preventive Services Task Force has recommended low-dose aspirin for the combined prevention of cardiovascular disease and colorectal cancer (CRC) in adults aged 50–59 who have elevated heart risk, are not at increased risk of bleeding, have a life expectancy of at least 10 years, and are willing to take aspirin daily for that whole period.\u003c\/p\u003e\n\n\u003cp\u003eHowever, results from major Western trials have been mixed. The famous US Women's Health Study, which randomly assigned nearly 40,000 women (19,934 taking 100 mg aspirin every other day versus 19,942 on placebo) over 13 years, found that aspirin did not reduce cancer incidence at any site. In contrast, the US National Health and Nutrition Examination Survey (NHANES) followed 12,668 people for 14 years and found aspirin use was linked to a significant 17% reduction in overall cancer, a 30% reduction in breast cancer, and a 32% reduction in lung cancer.\u003c\/p\u003e\n\n\u003cp\u003eAnother set of studies pooled data from two British trials — the British Doctors Aspirin Trial (5,139 male doctors assigned 500 mg aspirin daily or placebo in a 2:1 ratio for 6 years, followed up to 17 years) and the UK Transient Ischaemic Attack Aspirin Trial (2,449 subjects given 1,200 mg or 300 mg aspirin for up to 8 years, followed up to 15 years). Together, these trials showed that aspirin reduced the risk of colorectal cancer by 26%, but had no effect on other cancers.\u003c\/p\u003e\n\n\u003cp\u003eYet another US study — the Cancer Prevention Study II Nutrition Cohort — followed 146,113 people for up to 12 years and found that those taking at least 325 mg of aspirin daily for more than 5 years had a 19% lower risk of prostate cancer and a 32% lower risk of colorectal cancer. More recent data from the Nurses' Health Study (12,710 people followed up to 31 years) and the Health Professionals Follow-up Study (15,275 people followed up to 27 years) found that regular aspirin use reduced the risk of gastrointestinal (GI)-related cancers by 15% and colorectal cancer by 19%.\u003c\/p\u003e\n\n\u003cp\u003eWhy were these findings so inconsistent? The authors point out several reasons: different study designs, limited sample sizes, different follow-up durations, and, importantly, the fact that in the United States, aspirin is an over-the-counter drug available in any pharmacy. This made it difficult for researchers to define a \"clean\" control group of people who never took aspirin. Furthermore, almost all of these studies were conducted in Western countries, and large cohort studies investigating aspirin's cancer benefits in Asian populations — including China — were largely absent. This is exactly the gap the current Hong Kong study aimed to fill.\u003c\/p\u003e\n\n\u003ch2 id=\"study-methods\"\u003eStudy Methods: How the Research Was Conducted\u003c\/h2\u003e\n\n\u003cp\u003eThis study utilized a powerful resource: the electronic medical records of the Hong Kong Hospital Authority, which provides healthcare services and medications to the entire population of over seven million people at almost no cost. Because of this centralized system, the records capture essentially all patient activities across all public hospitals and clinics — including 6 million primary care attendees, 9.6 million specialist outpatient visits, and 1.63 million inpatient\/day-patient services across 73 primary care clinics, 47 specialist outpatient clinics, and 42 public hospitals (in the year 2014–2015 alone).\u003c\/p\u003e\n\n\u003cp\u003eThe data was extracted from the Hospital Authority Clinical Data Repository (also known as the Clinical Management System), a central electronic medical record system that logs all patients' demographics, prescription details, and clinical diagnoses using the International Classification of Diseases (ICD-9 or ICD-10) codes. The research team also obtained ethical approval from the Joint Chinese University of Hong Kong – New Territories East Cluster Clinical Research Ethics Committee.\u003c\/p\u003e\n\n\u003ch3\u003eWho was included?\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eAny patient over 18 years old who was prescribed aspirin for any medical reason between 2000 and 2004 at any public inpatient or outpatient service, with prescriptions totaling \u003cstrong\u003eat least 6 months\u003c\/strong\u003e of use.\u003c\/li\u003e\n  \u003cli\u003ePatients prescribed aspirin for less than 6 months were excluded, as were patients who could not be matched to a comparison subject.\u003c\/li\u003e\n  \u003cli\u003eEvery aspirin user was matched by age (±2 years) and sex with \u003cstrong\u003etwo randomly selected non-aspirin users\u003c\/strong\u003e from the same database — a 1:2 ratio.\u003c\/li\u003e\n  \u003cli\u003eNon-aspirin users who died before the \"matching date\" were excluded to reduce a statistical distortion known as \"immortal time bias.\"\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe initial database contained 4,564,100 patients from 2000 to 2004. Of these, 254,489 (5.6%) had been prescribed aspirin during that period. After excluding 48,920 (19.2%) who had aspirin for less than 6 months and 1,399 (0.5%) who couldn't be matched, the final sample included \u003cstrong\u003e612,509 patients\u003c\/strong\u003e: 204,170 aspirin users (33.3%) and 408,339 non-aspirin users (66.6%). All patients were followed until the end of 2013 — giving up to 14 years of follow-up — or until death, whichever came first.\u003c\/p\u003e\n\n\u003ch3\u003eWhat medications and conditions were tracked?\u003c\/h3\u003e\n\u003cp\u003eBeyond aspirin itself, the researchers documented the use of many other medications that might affect cancer risk, including:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eNon-steroidal anti-inflammatory drugs (NSAIDs)\u003c\/li\u003e\n  \u003cli\u003eOther antiplatelet agents (besides aspirin)\u003c\/li\u003e\n  \u003cli\u003eAnticoagulants (warfarin, direct oral anticoagulants)\u003c\/li\u003e\n  \u003cli\u003eAntisecretory medications — proton pump inhibitors (PPIs) and H₂-antagonists (H2B)\u003c\/li\u003e\n  \u003cli\u003eStatins, metformin, sulphonylurea, insulin, glitazones, and alpha-glucosidase inhibitors (drugs that reflect diabetes and metabolic conditions)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThey also identified underlying conditions using ICD-9 codes, including ischemic heart disease (ICD-9: 410–414), heart failure (ICD-9: 428), cerebrovascular disease (ICD-9: 430–438), diabetes mellitus, and hypertension. Cancer diagnoses were extracted using ICD-9 codes and classified as GI-related (oesophagus, liver, pancreas, stomach, colorectum) and non-GI related (lung, breast, kidney, bladder, prostate, leukaemia, multiple myeloma). If a patient had more than one cancer diagnosis during follow-up, each was counted separately.\u003c\/p\u003e\n\n\u003ch3\u003eHow was the data analyzed?\u003c\/h3\u003e\n\u003cp\u003eThe researchers used Cox proportional hazards regression models — a standard statistical technique used to estimate the risk of an event over time — with inverse probability (IP) weights. The IP weighting technique adjusted for the time-varying use of the 10 other drugs mentioned above, since drug usage can indirectly reflect a patient's underlying health conditions (e.g., diabetic patients are usually prescribed metformin, and heart patients are usually prescribed warfarin). Hazard ratios were computed as estimates of age- and sex-adjusted relative risks (RR) with 95% confidence intervals (CIs).\u003c\/p\u003e\n\n\u003cp\u003eA key statistical detail: because the researchers were testing multiple cancer types at once (which increases the risk of a \"false positive\"), they set the threshold for statistical significance at an alpha level of \u003cstrong\u003e0.005\u003c\/strong\u003e rather than the conventional 0.05. This means the results are quite robust. Subgroup analyses were also performed by gender and age groups (below 65 years and 65 years or above).\u003c\/p\u003e\n\n\u003ch2 id=\"key-findings\"\u003eKey Findings: Detailed Results with All Data\u003c\/h2\u003e\n\n\u003ch3\u003eBaseline characteristics of the study population\u003c\/h3\u003e\n\u003cp\u003eThe mean age of the 612,509 participants was 67.5 years (standard deviation 12.0 years). The majority were over 65: 308,343 patients (50.3%) were between 65 and 79 years old, and 89,225 (14.6%) were 80 or above. Just over half (53.9%) were male.\u003c\/p\u003e\n\n\u003cp\u003eThe average duration of aspirin prescription was \u003cstrong\u003e7.7 years\u003c\/strong\u003e (SD 4.4 years). The median aspirin dose was \u003cstrong\u003e80 mg\u003c\/strong\u003e (interquartile range: 80 mg to 100 mg) — confirming this was truly a low-dose study. Importantly, 78,195 patients (38.3%) had aspirin prescribed for at least 10 years, and 50,247 of them (24.6%) took it continuously throughout the entire follow-up period.\u003c\/p\u003e\n\n\u003cp\u003eNot surprisingly, patients taking aspirin had a much higher burden of chronic disease compared to non-users, which reflects the main reason they were prescribed aspirin in the first place. Specifically, in the aspirin group compared to non-users:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eCardiovascular disease: 48.4% vs. 7.4%\u003c\/li\u003e\n  \u003cli\u003eIschemic heart disease: 26.7% vs. 6.0%\u003c\/li\u003e\n  \u003cli\u003eHeart failure: 40.7% vs. 3.0%\u003c\/li\u003e\n  \u003cli\u003eCerebrovascular disease: 35.3% vs. 6.3%\u003c\/li\u003e\n  \u003cli\u003eDiabetes mellitus: 38.0% vs. 18.0%\u003c\/li\u003e\n  \u003cli\u003eHypertension: 94.7% vs. 62.7%\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAspirin users were also more likely to be taking anticoagulants (26.7% vs. 3.7%), other antiplatelet agents (29.2% vs. 1.4%), H₂-blockers (78.4% vs. 52.0%), and proton pump inhibitors (46.4% vs. 22.8%). This pattern is expected because aspirin can irritate the stomach, so protective gastric medications are often prescribed alongside it.\u003c\/p\u003e\n\n\u003ch3\u003eOverall cancer incidence\u003c\/h3\u003e\n\u003cp\u003eA total of 97,684 cancer cases (15.9% of all participants) were observed during the follow-up period. The most common cancer was lung cancer — 6,142 cases (3.0%) in the aspirin group versus 18,766 (4.6%) in the non-aspirin group. Colorectal cancer was second, with 5,118 (2.5%) cases among aspirin users and 13,336 (3.3%) among non-users.\u003c\/p\u003e\n\n\u003cp\u003eStrikingly, cancer at any site occurred in \u003cstrong\u003e26,929 aspirin users (13.2%) compared to 70,755 non-aspirin users (17.3%)\u003c\/strong\u003e. After statistical adjustment, this translates to a \u003cstrong\u003e25% significantly reduced risk of overall cancer\u003c\/strong\u003e for aspirin users (RR: 0.75; 95% CI: 0.73–0.77; p\u0026lt;0.001). In plain language, for every 100 people NOT taking aspirin, about 17 developed cancer over 10 years; among 100 aspirin users, only about 13 did.\u003c\/p\u003e\n\n\u003ch3\u003eGI-related cancers: dramatic reductions\u003c\/h3\u003e\n\u003cp\u003eThe protective effect of aspirin was most pronounced for cancers of the digestive system. Here are the specific relative risks, with the key number being the percentage of risk reduction:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStomach cancer: 58% lower risk\u003c\/strong\u003e (RR: 0.42; 95% CI: 0.38–0.46) — the strongest protective effect observed\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLiver cancer: 51% lower risk\u003c\/strong\u003e (RR: 0.49; 95% CI: 0.45–0.53)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePancreatic cancer: 46% lower risk\u003c\/strong\u003e (RR: 0.54; 95% CI: 0.47–0.62)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOesophageal cancer: 41% lower risk\u003c\/strong\u003e (RR: 0.59; 95% CI: 0.52–0.67)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eColorectal cancer: 29% lower risk\u003c\/strong\u003e (RR: 0.71; 95% CI: 0.67–0.75)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eAll of these results were highly statistically significant (p\u0026lt;0.001).\u003c\/p\u003e\n\n\u003ch3\u003eNon-GI cancers: benefits in lung and leukaemia, but a red flag for breast cancer\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLung cancer: 35% lower risk\u003c\/strong\u003e (RR: 0.65; 95% CI: 0.62–0.68; p\u0026lt;0.001)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLeukaemia: 33% lower risk\u003c\/strong\u003e (RR: 0.67; 95% CI: 0.57–0.79; p\u0026lt;0.001)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBreast cancer (female only): 14% INCREASED risk\u003c\/strong\u003e (RR: 1.14; 95% CI: 1.04–1.25; p=0.004)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFor several other cancer types, there was no statistically meaningful association with aspirin use:\n  \u003c\/p\u003e\u003cul\u003e\n    \u003cli\u003eKidney cancer: RR 1.01 (95% CI: 0.88–1.15; p=0.926)\u003c\/li\u003e\n    \u003cli\u003eBladder cancer: RR 1.06 (95% CI: 0.98–1.14; p=0.174)\u003c\/li\u003e\n    \u003cli\u003eProstate cancer (male only): RR 0.95 (95% CI: 0.88–1.03; p=0.177)\u003c\/li\u003e\n    \u003cli\u003eMultiple myeloma: RR 0.95 (95% CI: 0.81–1.11; p=0.489)\u003c\/li\u003e\n  \u003c\/ul\u003e\n\n\n\u003cp\u003eThe increased breast cancer risk is particularly noteworthy. While the paper reports that this increased risk was especially pronounced among women with very long-term aspirin use, it is important to note that the absolute numbers were identical (1.6% in both groups), and the statistical significance (p=0.004) is right at the stringent cut-off used in this study. This finding stands in contrast to some Western studies (like NHANES, which found a 30% breast cancer reduction) and certainly requires further investigation.\u003c\/p\u003e\n\n\u003ch2 id=\"subgroup-analysis\"\u003eSubgroup Analysis: Timing, Gender, and Age\u003c\/h2\u003e\n\n\u003cp\u003eTo understand how the duration of aspirin use affects cancer protection, the researchers re-ran the analysis at two earlier time points. This is a crucial methodological step, because it shows whether the benefits appear early or only after many years of use.\u003c\/p\u003e\n\n\u003ch3\u003eEarly follow-up (end of 2006): aspirin use less than 7 years (mean duration 3.9 years)\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eOverall cancer risk: 33% reduced (RR: 0.67; 95% CI: 0.65–0.69)\u003c\/li\u003e\n  \u003cli\u003eLiver cancer: RR 0.41; Stomach: RR 0.36; Colorectum: RR 0.67\u003c\/li\u003e\n  \u003cli\u003eLung: RR 0.56; Leukaemia: RR 0.60\u003c\/li\u003e\n  \u003cli\u003eBreast cancer: RR 1.04 (not statistically significant)\u003c\/li\u003e\n  \u003cli\u003eProstate cancer: RR 0.87 (95% CI: 0.80–0.95) — actually significant at this early timepoint, though it lost significance by the end of 2013\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eMid follow-up (end of 2009): aspirin use less than 10 years (mean duration 5.7 years)\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eOverall cancer risk: 40% reduced (RR: 0.60; 95% CI: 0.59–0.62) — the strongest overall protection seen at any timepoint\u003c\/li\u003e\n  \u003cli\u003eLiver cancer: RR 0.34; Stomach: RR 0.32; Colorectum: RR 0.57\u003c\/li\u003e\n  \u003cli\u003eLung: RR 0.50; Multiple myeloma: RR 0.76 (significant at this point)\u003c\/li\u003e\n  \u003cli\u003eBreast cancer: RR 0.97 — no longer elevated\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eFinal follow-up (end of 2013): aspirin use up to 14 years (mean duration 7.7 years)\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eOverall cancer risk: 25% reduced (RR: 0.75)\u003c\/li\u003e\n  \u003cli\u003eThe pattern of protection remained, though slightly attenuated\u003c\/li\u003e\n  \u003cli\u003eBreast cancer risk reappeared as significantly increased (RR: 1.14)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe researchers note that the chemoprotective benefits of aspirin are \"moderately reduced\" with truly long-term use for some cancers, yet the breast cancer risk \"significantly increased through the long-term use of aspirin.\" The chemoprotective effect of aspirin was comparable for both genders and across age groups (below 65 years vs. 65 years and above).\u003c\/p\u003e\n\n\u003ch2 id=\"clinical-implications\"\u003eClinical Implications: What This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThis study provides some of the strongest evidence to date that long-term, low-dose aspirin (80 mg per day) is associated with meaningful protection against a broad range of cancers in an Asian population. The magnitude of effect is striking — a 25% reduction in overall cancer risk, with reductions of 29–58% for specific GI cancers. To put this in perspective, an informal international consensus statement released in 2009 already categorized the chemoprotective effects of aspirin as \"very probable.\"\u003c\/p\u003e\n\n\u003cp\u003eThe authors suggest two possible explanations for why their findings are more dramatic than many Western trials:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGenetic differences:\u003c\/strong\u003e The Chinese population may respond differently to aspirin than Western populations; genetic variations affecting drug metabolism and inflammatory pathways may modulate the chemopreventive effect.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTremendous statistical power:\u003c\/strong\u003e With over 600,000 participants from a complete population database, the study can detect effects that smaller trials might miss.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe study also aligns with findings from other Asian populations. A Taiwanese study using the National Health Insurance Research Database matched 1,985 low-dose aspirin users (50–150 mg daily for at least 3.5 years) with 7,490 non-users and found a dramatically lower risk of colorectal cancer (adjusted HR: 0.50; 95% CI: 0.28–0.87) over a median follow-up of 8.9 years. A case-control study in Shanghai, China, with 761 pancreatic cancer cases and 794 matched population controls, found that aspirin users had a 46% lower risk of pancreatic cancer (OR: 0.54; 95% CI: 0.40–0.73).\u003c\/p\u003e\n\n\u003cp\u003eWhat makes this Hong Kong study unique is the purity of its comparison groups. In Hong Kong, aspirin for cancer prevention is essentially unheard of — patients are rarely prescribed aspirin for anything other than cardiovascular or cerebrovascular disease prevention, and aspirin is not readily available over-the-counter. This means the \"non-aspirin group\" truly consists of people who never took aspirin, avoiding the \"contamination\" problem that plagued many US studies where aspirin was freely purchased in pharmacies.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations: What This Study Couldn't Prove\u003c\/h2\u003e\n\n\u003cp\u003eWhile this study is impressive in scale, it has important limitations that should be considered before jumping to conclusions.\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eObservational design, not a randomized controlled trial:\u003c\/strong\u003e This is a retrospective cohort study. While the researchers used sophisticated statistical methods (including inverse probability weighting) to adjust for known confounding factors, it is impossible to fully eliminate the possibility that some unmeasured factor explains the differences in cancer rates between aspirin users and non-users. Randomized trials are still the \"gold standard\" for proving cause and effect.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eConfounding by medical condition:\u003c\/strong\u003e Patients prescribed aspirin had dramatically higher rates of heart disease, stroke, diabetes, and hypertension (as shown in Table 1). Although the analysis adjusted for drug use as a proxy for these conditions, residual confounding is possible. Interestingly, having these conditions typically INCREASES cancer risk, which makes the reduced cancer rates in the aspirin group even more notable — but it also means the two groups were fundamentally different in their health profiles.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGeneralizability:\u003c\/strong\u003e The findings come from a Chinese population in Hong Kong with a centralized public healthcare system. The results may not generalize to other ethnic groups, healthcare settings, or countries where aspirin is used differently.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eInformation on dose and indication:\u003c\/strong\u003e While the median dose was clearly low (80 mg), the study did not restrict aspirin use by indication or dosage. Some patients may have taken higher doses or taken it inconsistently.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLimited access to full records:\u003c\/strong\u003e Due to restrictions on academic institutes accessing the entire electronic health system, the researchers could only extract aspirin users and match them with non-users — they could not analyze the full population in a more open-ended way.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThe breast cancer paradox:\u003c\/strong\u003e The finding of an increased breast cancer risk (RR: 1.14) is puzzling and contradicts some Western studies. Because the confidence interval is narrow (1.04–1.25) and the p-value (0.004) meets the stringent threshold, this is unlikely to be pure chance. However, it highlights that aspirin's effects are not uniformly beneficial across all cancer types.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations: Actionable Advice for Patients\u003c\/h2\u003e\n\n\u003cp\u003eBased on this study, here is what patients should consider:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDon't start aspirin for cancer prevention without talking to your doctor.\u003c\/strong\u003e Even though the cancer protection numbers look impressive, aspirin carries real risks — most notably gastrointestinal bleeding and hemorrhagic stroke. This study did not measure bleeding complications, so a full risk-benefit analysis cannot be made from it alone.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf you already take low-dose aspirin for heart disease or stroke prevention, take some reassurance from this study.\u003c\/strong\u003e The people in this study who took aspirin had a substantially lower risk of many cancers — an additional bonus to the cardiovascular benefits they were seeking.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePay attention to cancer screening.\u003c\/strong\u003e Even with a 29% reduction in colorectal cancer, aspirin users still developed 5,118 cases of colorectal cancer. Aspirin is not a substitute for colonoscopies, mammograms, or other proven screening tests.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWomen should be particularly aware of the breast cancer finding.\u003c\/strong\u003e The modest 14% increased risk observed in this study needs to be weighed against the benefits. Discuss your personal risk factors with your physician.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThe dose matters.\u003c\/strong\u003e The median dose in this study was 80 mg — a \"baby aspirin\" dose commonly used for heart protection. Higher doses may not offer additional cancer benefits and likely increase side effects.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDuration matters.\u003c\/strong\u003e The protective effects appear even with relatively short-term use (the benefits were visible by the end of 2006, with a mean aspirin duration of 3.9 years), though the strongest overall protection was seen at the 10-year mark.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe authors themselves are appropriately cautious: \"Further investigation is needed before promoting aspirin as a primary chemoprotective agent.\" This is a wise stance. While this study adds powerful evidence supporting aspirin's role in cancer prevention, the decision to take daily aspirin must be individualized, factoring in cardiovascular risk, cancer risk, bleeding risk, age, sex, and patient preferences.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat did the 10-year Hong Kong study find about low-dose aspirin and cancer risk?\u003c\/h3\u003e\n\u003cp\u003eIn a study of over 600,000 people in Hong Kong, those who took low-dose aspirin (median 80 mg daily) for at least 6 months had a 25% lower overall cancer risk than non-users. Reductions were seen for stomach, liver, pancreatic, oesophageal, colorectal, lung, and leukaemia cancers, but breast cancer risk was 14% higher in women.\u003c\/p\u003e\n\u003ch3\u003eWere there any cancers where aspirin increased risk?\u003c\/h3\u003e\n\u003cp\u003eYes. In women, aspirin use was associated with a 14% increased risk of breast cancer (RR 1.14; 95% CI 1.04–1.25; p=0.004). The absolute numbers were identical (1.6% in both groups). This finding contrasts with some Western studies and requires further investigation. No significant associations were found for kidney, bladder, prostate, or multiple myeloma cancers.\u003c\/p\u003e\n\u003ch3\u003eDoes the study prove that aspirin prevents cancer?\u003c\/h3\u003e\n\u003cp\u003eNo. This was an observational cohort study, not a randomized controlled trial. While it adjusted for many factors, it cannot prove cause and effect. The authors state that further investigation is needed before promoting aspirin as a primary chemoprotective agent. Randomized trials remain the gold standard for proving cause and effect.\u003c\/p\u003e\n\u003ch3\u003eShould I start taking daily aspirin to prevent cancer?\u003c\/h3\u003e\n\u003cp\u003eDo not start aspirin for cancer prevention without talking to your doctor. Aspirin carries real risks, including gastrointestinal bleeding and hemorrhagic stroke, which this study did not measure. If you already take low-dose aspirin for heart disease or stroke prevention, this study offers some reassurance of an additional cancer-risk reduction, but the decision must be individualized.\u003c\/p\u003e\n\u003ch3\u003eShould I get a second opinion before starting daily low-dose aspirin to prevent cancer?\u003c\/h3\u003e\n\u003cp\u003eA second opinion is reasonable before starting aspirin solely for cancer prevention. Long-term low-dose aspirin is linked to a 25% lower overall cancer risk, with 29–58% reductions for several gastrointestinal cancers, but also a 14% increased breast cancer risk in women. Aspirin carries bleeding and hemorrhagic stroke risks, and this study did not measure bleeding complications. The decision must be individualized, weighing cardiovascular risk, cancer risk, bleeding risk, age, sex, and preferences. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal Article:\u003c\/strong\u003e \"Long-term use of low-dose aspirin for cancer prevention: A 10-year population cohort study in Hong Kong\"\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Kelvin K.F. Tsoi, Jason M.W. Ho, Felix C.H. Chan, and Joseph J.Y. Sung\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e International Journal of Cancer (Int. J. Cancer), Volume 145, pages 267–273; Published online December 21, 2018; © 2018 UICC\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e 10.1002\/ijc.32083\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAffiliations:\u003c\/strong\u003e Stanley Ho Big Data Decision Analytics Research Centre, Jockey Club School of Public Health and Primary Care, and Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\/Conflict of Interest:\u003c\/strong\u003e The authors declared no conflicts of interest.\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eNote: This patient-friendly article is based on peer-reviewed research. It is intended for educational purposes only and should not replace professional medical advice. Always consult your physician before starting, stopping, or changing any medication.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47699401506972,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/ja\/products\/can-a-daily-low-dose-aspirin-help-prevent-cancer-insights-from-a-10-year-hong-kong-study","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}